Ethyol data

University researchers presented results in 200 patients with advanced ovarian cancer, randomized to treatment with the company's drug plus cyclophosphamide and cisplatin or to chemotherapy alone, showing that 9 percent of patients receiving the agent discontinued chemotherapy due to toxicities, as compared to 39 percent in the control group.

The dropout rate did not accelerate with cumulative rounds of chemotherapy in the group that got the drug, as it did for the control group. ...